Please login to the form below

Not currently logged in
Email:
Password:

XLH

This page shows the latest XLH news and features for those working in and with pharma, biotech and healthcare.

SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

XLH is usually first observed in infants and is characterised by bowed or bent legs, a short stature, bone pain and delayed walking. ... An application for the extended use of Crysvita in adults with XLH is also currently under review by the EMA.

Latest news

  • NICE U-turn on Crystiva for rare bone disease NICE U-turn on Crystiva for rare bone disease

    This marks a step change in treatment for XLH, emphasised through the emotional testimonies provided by patient groups and clinicians following the first evaluation consultation.”. ... Characterised by bowed or bent legs, a short stature, bone pain and

  • NICE set to reject Kyowa Kirin’s Crysvita for XLH NICE set to reject Kyowa Kirin’s Crysvita for XLH

    The twice-monthly injection was given a conditional approval by the European Medicines Agency (EMA) earlier this year to treat children and young people with X-linked hypophosphataemia (XLH), a genetic ... XLH only affects around 250 children and young

  • Rigel and Ultragenyx claim approvals for rare drugs Rigel and Ultragenyx claim approvals for rare drugs

    Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... Ultragenyx’s FDA approval was for Crysvita (burosumab), which has become the first approved drug for adults and children ages one year and older with X-linked

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics